newsfilter
← Earnings
Earnings Releases·

MBX Biosciences — Third Quarter 2026 Earnings Summary

  • Q3 2026 net loss widened to $62.4 million from $21.6 million in the prior year period, driven by a 66% increase in G&A expenses to $34.3 million and a 66% rise in R&D expenses to $32.0 million; total operating expenses for the nine months ended September 30, 2026, reached $134.5 million versus $72.3 million in 2025.
  • Cash and marketable securities increased to $481.6 million as of September 30, 2026, from $373.7 million at year-end 2025, following $97.6 million in net proceeds from an ATM stock sale, providing a cash runway to fund operations into 2029.
  • Pivotal Phase 3 oPTimize trial for canvuparatide initiated patient dosing in August 2026 with enrollment of approximately 160 adults, while unblinded 12-week MAD data for obesity candidate MBX 4291 is scheduled for release in Q4 2026.
  • The company appointed Peter Radovich to the Board of Directors in October 2026 and Jeff Held as Chief Legal Officer in September 2026, while G&A expenses included $20.8 million in stock-based compensation related to former CEO award modifications.
Company
MBX BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology